|
RU2294203C2
(en)
*
|
2001-12-21 |
2007-02-27 |
Дзе Проктер Энд Гэмбл Компани |
Method for treatment of osseous disorders
|
|
JP5462429B2
(en)
*
|
2002-01-16 |
2014-04-02 |
アステラス製薬株式会社 |
Pharmaceutical composition for improving oral absorption
|
|
PL399493A1
(en)
*
|
2002-05-10 |
2012-11-05 |
F. Hoffmann-La Roche Ag |
Bisphosphonic acids for the treatment and prevention of osteoporosis
|
|
FR2841138B1
(en)
*
|
2002-06-25 |
2005-02-25 |
Cll Pharma |
SOLID PHARMACEUTICAL COMPOSITION COMPRISING A LIPOPHILIC ACTIVE INGREDIENT, ITS PREPARATION PROCESS
|
|
US20060024366A1
(en)
*
|
2002-10-25 |
2006-02-02 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
|
US20060003004A1
(en)
*
|
2002-10-25 |
2006-01-05 |
Collegium Pharmaceutical, Inc. |
Pulsatile release compositions of milnacipran
|
|
US20040132826A1
(en)
*
|
2002-10-25 |
2004-07-08 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
|
ES2291749T5
(en)
*
|
2002-12-20 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
FORMULATION OF HIGH DOSES OF IBANDRONATO.
|
|
TWI355276B
(en)
*
|
2003-01-14 |
2012-01-01 |
Akira Tsuji |
Gastrointestinal absorption enhancer mediated by p
|
|
FR2850577B1
(en)
*
|
2003-02-03 |
2005-04-15 |
Ethypharm Sa |
MASK TASTE ENRICHED PARTICLES, PROCESS FOR THEIR PREPARATION AND ORODISPERSIBLE COMPRESSES CONTAINING SAID PARTICLES
|
|
ZA200409537B
(en)
*
|
2003-01-31 |
2006-10-25 |
Yamanouchi Pharma Co Ltd |
Stable solid medicinal composition for oral administration
|
|
US7442387B2
(en)
*
|
2003-03-06 |
2008-10-28 |
Astellas Pharma Inc. |
Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
|
|
TR200300510A2
(en)
*
|
2003-04-18 |
2004-11-22 |
Sanovel �La� Sanay� Ve T�Caret A.�. |
Dispersing alendronate microparticle formulation
|
|
US7358270B2
(en)
*
|
2004-01-30 |
2008-04-15 |
Astellas Pharma Inc. |
Treating agent for irritable bowel syndrome
|
|
US20050182028A1
(en)
*
|
2004-02-13 |
2005-08-18 |
Chen Chih-Ming J. |
Pharmaceutical formulation for oral delivery of bisphosphates
|
|
RU2359678C2
(en)
*
|
2004-05-24 |
2009-06-27 |
Дзе Проктер Энд Гэмбл Компани |
Medicinal forms on basis of biphosphonates
|
|
KR101238525B1
(en)
*
|
2004-12-31 |
2013-02-28 |
레디 유에스 테라퓨틱스 인코포레이티드 |
Novel benzylamine derivatives as cetp inhibitors
|
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
|
JP4632204B2
(en)
*
|
2005-09-21 |
2011-02-16 |
アステラス製薬株式会社 |
Antidiarrheal irritable bowel syndrome treatment
|
|
JP2009524675A
(en)
*
|
2006-01-24 |
2009-07-02 |
パラテック ファーマシューティカルズ インコーポレイテッド |
Methods to increase the oral bioavailability of tetracycline
|
|
KR101784001B1
(en)
|
2006-04-04 |
2017-10-23 |
케이지 액퀴지션 엘엘씨 |
Oral dosage forms including an antiplatelet agent and an acid inhibitor
|
|
US20090074872A1
(en)
*
|
2006-06-26 |
2009-03-19 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
|
AU2007265452A1
(en)
*
|
2006-06-26 |
2008-01-03 |
Mutual Pharmaceutical Company, Inc. |
Active agent formulations, methods of making, and methods of use
|
|
WO2008012830A1
(en)
*
|
2006-07-28 |
2008-01-31 |
Hetero Drugs Limited |
Soup faropenem free acid
|
|
WO2008078922A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Yuhan Corporation |
Revaprazan-containing solid dispersion and process for the preparation thereof
|
|
WO2008081829A1
(en)
|
2006-12-27 |
2008-07-10 |
Astellas Pharma Inc. |
Aminoalkylmethacrylate copolymer e for maintaining solubility of poorly water-soluble drug
|
|
US7605148B2
(en)
*
|
2007-04-16 |
2009-10-20 |
Aurobindo Pharma Ltd. |
Aqueous oral solution of bisphosphonic acid
|
|
CN101702878B
(en)
*
|
2007-05-11 |
2012-11-28 |
弗·哈夫曼-拉罗切有限公司 |
Pharmaceutical compositions for poorly soluble drugs
|
|
KR101007865B1
(en)
*
|
2007-06-18 |
2011-01-14 |
연세대학교 산학협력단 |
Sustained-release chitosan capsules comprising chitosan and phytic acid
|
|
DE102007060175A1
(en)
|
2007-12-13 |
2009-06-18 |
Johannes Gutenberg-Universität Mainz |
Quaternization of the additive aminoalkyl methacrylate copolymer E to improve the permeability and solubility of drugs
|
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
|
CN101548978B
(en)
*
|
2008-04-03 |
2012-11-21 |
万特制药(海南)有限公司 |
Pharmaceutical composition containing alendronate sodium
|
|
US20100159010A1
(en)
*
|
2008-12-24 |
2010-06-24 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
|
KR101647869B1
(en)
*
|
2009-07-30 |
2016-08-11 |
에보니크 룀 게엠베하 |
Powdery or granulated composition comprising a copolymer, a dicarboxylic acid and a fatty monocarboxylic acid
|
|
CN105419206B
(en)
*
|
2009-07-30 |
2017-12-15 |
赢创罗姆有限公司 |
Powdered or granular composition comprising copolymer, dicarboxylic acids and aliphatic mono-carboxylic acids
|
|
US9169279B2
(en)
|
2009-07-31 |
2015-10-27 |
Thar Pharmaceuticals, Inc. |
Crystallization method and bioavailability
|
|
ES2650665T3
(en)
|
2009-07-31 |
2018-01-19 |
Grünenthal GmbH |
Crystallization and bioavailability method
|
|
US20160016982A1
(en)
|
2009-07-31 |
2016-01-21 |
Thar Pharmaceuticals, Inc. |
Crystallization method and bioavailability
|
|
FR2954320B1
(en)
|
2009-12-17 |
2012-06-15 |
Cll Pharma |
SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS
|
|
WO2011103920A2
(en)
|
2010-02-25 |
2011-09-01 |
Evonik Röhm Gmbh |
Pharmaceutical or neutraceutical formulation
|
|
WO2011141192A1
(en)
|
2010-05-10 |
2011-11-17 |
Evonik Röhm Gmbh |
Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
|
|
JP5888612B2
(en)
|
2010-06-23 |
2016-03-22 |
アステラス製薬株式会社 |
Crystals of condensed pyridine compound salts
|
|
CN102309442A
(en)
*
|
2010-07-07 |
2012-01-11 |
澳美制药厂 |
Ambroxol hydrochloride oral aqueous composition and preparation method thereof
|
|
US9011912B2
(en)
|
2010-10-07 |
2015-04-21 |
Abon Pharmaceuticals, Llc |
Extended-release oral dosage forms for poorly soluble amine drugs
|
|
WO2012071517A2
(en)
|
2010-11-24 |
2012-05-31 |
Thar Pharmaceuticals, Inc. |
Novel crystalline forms
|
|
CN103391769A
(en)
|
2011-02-17 |
2013-11-13 |
霍夫曼-拉罗奇有限公司 |
A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
|
|
CN102144982B
(en)
*
|
2011-03-30 |
2012-12-12 |
江苏神龙药业有限公司 |
Minodronate tablets and preparation method thereof
|
|
FR2975300B1
(en)
*
|
2011-05-19 |
2013-06-07 |
Thierry Breul |
PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY
|
|
CN102949358B
(en)
*
|
2011-08-17 |
2015-10-21 |
山东新时代药业有限公司 |
A kind of minodronic acid tablet and preparation method thereof
|
|
US9199967B2
(en)
|
2011-08-18 |
2015-12-01 |
Dr. Reddy's Laboratories Ltd. |
Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
|
|
CA2850022C
(en)
|
2011-09-27 |
2018-05-01 |
Dr. Reddy's Laboratories, Ltd. |
5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
|
|
US20140128431A1
(en)
|
2012-04-03 |
2014-05-08 |
Hoffmann-Laroche Inc. |
Pharmaceutical composition with improved bioavailability, safety and tolerability
|
|
EP2649989B1
(en)
|
2012-04-13 |
2017-10-18 |
King Saud University |
Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
|
|
RU2015123632A
(en)
|
2012-11-19 |
2017-01-10 |
Др. Редди'С Лабораторис Лтд. |
PHARMACEUTICAL COMPOSITIONS OF CETR INHIBITORS
|
|
MY192032A
(en)
|
2013-01-22 |
2022-07-24 |
Hoffmann La Roche |
Pharmaceutical composition with improved bioavailability
|
|
KR102294577B1
(en)
*
|
2015-01-12 |
2021-08-26 |
엔터리스 바이오파마, 인크. |
solid oral dosage form
|
|
WO2017208070A1
(en)
|
2016-05-31 |
2017-12-07 |
Grünenthal GmbH |
Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
|